PARI & Lamira® Partnering to Treat NTM Lung Disease

PARI is always looking for new ways to work with pharmaceutical companies in order to provide top quality medical devices for patients. In fact, PARI has an entire department, aptly named eFlow Technology Partnering, that focuses on cultivating licensed pharma partnerships, allowing eFlow Technology nebulizers to synergize with prescription drug formulations. Innovation and collaboration are of utmost importance when it comes to the healthcare solutions people need!

Most recently, PARI and Lamira® have been approved in Japan to collaborate in administering ARIKAYCE® (amikacin liposome inhalation suspension) to patients with nontuberculous mycobacterial (NTM) Lung Disease (also known as refractory MAC lung disease). This follows similar approvals in the United States and Europe for this drug-specific eFlow Technology nebulizer. 

Just what is eFlow technology? A part of the PARI eRapid Nebulizer System we sell here at Nebology, the eFlow is an electronic aerosol delivery platform that precisely vaporizes liquid medications through its rapidly vibrating mesh membrane. Devices that utilize eFlow Technology are designed to make treatment for patients with severe respiratory conditions much faster as well as more effective and accessible. 

Other features of eFlow Technology include the user-friendly LCD display, which provides information about battery charge levels, nebulizer cable connection status, and whether or not medicine has been added to your nebulizer cup. eFlow Technology like the eRapid also has flexible power options: use it with off-the-shelf batteries, rechargeable NiMH or lithium-ion batteries, or the included AC adapter that plugs into the wall. The eRapid is truly designed with the patient in mind.